UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 7, 2019

ADURO BIOTECH, INC.
(Exact name of Registrant as Specified in its Charter)

Delaware	**001-37345**	**94-3348934**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(I.R.S. Employer Identification No.)**

740 Heinz Avenue
Berkeley, California 94710
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (510) 848-4400

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 8.01. Other Events.

Attached hereto as Exhibit 99.1 is an investor presentation that Aduro Biotech, Inc. plans to present during the 37th Annual J.P. Morgan Healthcare Conference commencing on January 7, 2019.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Aduro Biotech, Inc. Investor Presentation.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 7, 2019

ADURO BIOTECH, INC.

By: /s/ Jennifer Lew
Name: Jennifer Lew
Title: Chief Financial Officer

Exhibit 99.1

Corporate Presentation

January 2019

ADURO BIOTECH



PIONEERING IMMUNOTHERAPY. TRANSFORMING LIVES.

Note Regarding Forward-Looking Statements

This presentation and the accompanying oral presentation include express and implied forward-looking statements regarding the current intentions, expectations, estimates, opinions and beliefs of Aduro Biotech, Inc. ("Aduro") that are not historical facts. These forward-looking statements include statements regarding Aduro's expectations for its product candidates (including their therapeutic and commercial potential, anticipated future development activities, anticipated timing of development activities, including initiation of clinical trials and presentations of clinical data and the indications Aduro and its collaborators plan to pursue), future results of operations and financial position, including current funds providing operating capital into 2021, business strategy, strategic collaborations, any royalty or milestone payments and Aduro's ability to obtain and maintain intellectual property protection for its product candidates. Such forward-looking statements may be identified by words such as "believes", "may", "will", "expects", "endeavors", "anticipates", "intends", "plans", "estimates", "projects", "should", "objective" and variations of such words and similar words. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, Aduro's history of net operating losses and uncertainty regarding its ability to achieve profitability, Aduro's ability to develop and commercialize its product candidates, Aduro's ability to use and expand its technology to build a pipeline of product candidates, Aduro's ability to obtain and maintain regulatory approval of its product candidates, Aduro's ability to operate in a competitive industry and compete successfully against competitors that have greater resources than it does, Aduro's reliance on third parties, and Aduro's ability to obtain and adequately protect intellectual property rights for its product candidates. Aduro discusses many of these risks in greater detail under the heading "Risk Factors" in its most recent Quarterly or Annual Report on Form 10-Q or Form 10-K filed with the Securities and Exchange Commission. Any forward-looking statements that Aduro makes in this presentation and the accompanying oral presentation speak only as of the date of these presentations. Except as required by law, Aduro assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date hereof.

Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or Aduro or any director, employee, agent, or adviser of Aduro. This presentation does not purport to be all-inclusive or to contain all of the information you may desire.

Aduro Corporate Highlights

STING	• Leadership in STING pathway biology • Advancing first-in-class STING agonist ADU-S100 + checkpoint inhibitors to address areas of high unmet need in oncology • cGAS-STING Pathway Inhibitor program aiming to treat autoimmune/inflammatory disease • Collaborations provide complementary capabilities
APRIL	• Innovative, wholly-owned anti-APRIL antibody BION-1301 in Phase 1/2 multiple myeloma study • BION-1301's differentiated mechanism of action will be evaluated in IgA Nephropathy in 2019
Financial Strength	• $278M at end of 3Q 2018 provides operating capital into 2021

Focus of Aduro Pipeline

Program		Target	Indication	Discovery	Preclinical	Phase 1	Phase 2	Partner
STING	**ADU-S100 (MIW815)**	STING	Multiple tumors					NOVARTIS
	ADU-S100 + spartalizumab	STING	Multiple tumors					NOVARTIS
	ADU-S100 + ipilimumab	STING	Melanoma					NOVARTIS
	ADU-S100 + anti-PD-1	STING	Head & Neck *(planned)*					NOVARTIS
	cGAS-STING pathway inhibitor program	cGAS-STING pathway	Autoimmune					Lilly
APRIL	**BION-1301**	APRIL	Multiple Myeloma					
	BION-1301	APRIL	IgA Nephropathy *(planned)*					

ADU-S100
STING Agonist



STING Plays a Critical Role in Activation of Tumor Immunity



- STimulator of INterferon Genes (STING) is a critical component of an innate immune pathway
  - STING protein function activated by cyclic dinucleotides
  - Immediate production of type I IFN and innate immunity
  - IFN-β is a signature cytokine of activated STING
- STING activation is required for rejection of cancer in various mouse models

ADURO BIOTECH

Key Attributes of ADU-S100 (MIW815) First-in-Class STING Agonist

- Demonstrated preclinical anti-tumor activity
  - Induces local innate immune activation – cytokine production – in injected tumors
  - Activates tumor-specific CD8+ T cells and systemic tumor rejection, bridging innate to adaptive immunity
  - Effectively combined with checkpoint inhibitors to enhance efficacy and durable immunity
- Well-tolerated and encouraging clinical signals in ongoing early phase trials
- Collaboration with Novartis provides $250M upfront, development cost share and profit share; Aduro leads U.S. commercialization



ADU-S100 (MIW815) bound to STING (X-ray crystal structure)

Advancing ADU-S100 (MIW815) Clinical Development

First-in-human clinical experience in heavily pre-treated patients with a diverse set of advanced cancers



ADURO BIOTECH

Phase 1 ADU-S100 (MIW815) Monotherapy Trial
Dose Escalation Reported



Meric-Bernstam et al. Phase I Dose-finding Study of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients With Advanced Solid Tumors or Lymphomas. Poster presented at: The Society for Immunotherapy of Cancer (SITC) Annual Meeting; November 7-11, 2018; Washington, D.C.

Phase 1 ADU-S100 (MIW815) Monotherapy Trial
Baseline Patient Demographics

All Patients (N=41)

Median age years (range)	Sex n (%)	Race n (%)	ECOG PS n (%)	Prior therapy with a checkpoint inhibitor n (%)	Number of prior regimens n (%)
62 (26–80)	Male 18 (43.9)	Caucasian 27 (65.9)	0 11 (26.8)	**Yes 22 (53.7)**	0 3 (7.3)
	Female 23 (56.1)	Black 6 (14.6)	1 30 (73.2)	No 19 (46.3)	1 4 (9.8)
		Asian 2 (4.9)			**≥2 34 (82.9)**
		Other/unknown 6 (14.6)			

Number of Tumor Types: 22

ECOG PS, Eastern Cooperative Oncology Group performance status.

Meric-Bernstam et al. Phase I Dose-finding Study of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients With Advanced Solid Tumors or Lymphomas. Poster presented at: The Society for Immunotherapy of Cancer (SITC) Annual Meeting; November 7-11, 2018; Washington, D.C.

Phase 1 ADU-S100 (MIW815) Monotherapy Trial
Safety and Tolerability

Adverse Event	%
≥1 any AE	78.0
Led to discontinuation	0.0
Grade ≥3	12.2
Led to death	0.0
AEs in ≥10% of patients	
Headache	14.6
Injection Site Pain	14.6
Pyrexia	14.6

- **No DLTs observed during the first cycle of treatment**
  - No patients discontinued treatment due to an AE
- Elevated lipase was the only Grade 3/4 suspected related AE reported in >1 patient (n=2; 4.9%)
- Treatment-emergent serious AEs were reported in 1 patient (Grade 3 dyspnea and Grade 4 respiratory failure at 1600 µg dose level)
  - This was related to underlying disease progression

Meric-Bernstam et al. Phase I Dose-finding Study of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients With Advanced Solid Tumors or Lymphomas. Poster presented at: The Society for Immunotherapy of Cancer (SITC) Annual Meeting; November 7-11, 2018; Washington, D.C.

Phase 1 ADU-S100 (MIW815) Monotherapy Trial
Time on Treatment and Response Evaluation



Data cut-off: August 16, 2018.
*Patient ongoing treatment at 13 months.
ER+, estrogen receptor-positive; HER2–, human epidermal growth factor receptor 2-negative; HER2+, HER2-positive; PD, progressive disease; PR, partial response; SD, stable disease; TNBC, triple-negative breast cancer.

Meric-Bernstam et al. Phase I Dose-finding Study of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients With Advanced Solid Tumors or Lymphomas. Poster presented at: The Society for Immunotherapy of Cancer (SITC) Annual Meeting; November 7-11, 2018; Washington, D.C.

ADURO BIOTECH

Phase 1 ADU-S100 (MIW815) Monotherapy Trial
Time on Treatment and Response Evaluation



Data cut-off: August 16, 2018.
*Patient ongoing treatment at 13 months.
ER+, estrogen receptor-positive; HER2–, human epidermal growth factor receptor 2-negative; HER2+, HER2-positive; PD, progressive disease; PR, partial response; SD, stable disease; TNBC, triple-negative breast cancer.

Meric-Bernstam et al. Phase I Dose-finding Study of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients With Advanced Solid Tumors or Lymphomas. Poster presented at: The Society for Immunotherapy of Cancer (SITC) Annual Meeting; November 7-11, 2018; Washington, D.C.

ADURO BIOTECH

Phase 1 ADU-S100 (MIW815) Monotherapy Trial
Systemic Signals of STING Target Engagement: IL-6, MCP1 and IFN-β

Systemic cytokines consistently observed > 800 mcg

Cytokines trend higher with repeat dosing



ADURO BIOTECH

Data Highlights from Phase 1 ADU-S100 (MIW815) Monotherapy Trial

Good safety profile	Well-tolerated in heavily pre-treated, heterogenous patient population
Preliminary signs of clinical and biomarker activity	• 2 of 40 patients treated had a PR, one patient received prior anti-PD-1 therapy • 11 patients achieved SD
Target engagement	Observed increases in key systemic cytokines, including IL-6, MCP-1 and IFN-ß, after ADU-S100 (MIW815) administration, indicating target engagement and activation of the STING pathway

Meric-Bernstam et al. Phase I Dose-finding Study of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients With Advanced Solid Tumors or Lymphomas. Poster presented at: The Society for Immunotherapy of Cancer (SITC) Annual Meeting; November 7-11, 2018; Washington, D.C.

Phase 1b ADU-S100 (MIW815) + spartalizumab (PDR001) Trial Ongoing

Phase 1b

Patients:
Cutaneously accessible, treatment-refractory, advanced or metastatic solid tumors or lymphomas

Primary Objective:
Safety and tolerability



Patients grouped in two dosing schedules, treated over 28-day Dosing Cycles until confirmed disease progression

ADURO BIOTECH

Preliminary Observations from Phase 1b ADU-S100 (MIW815) + spartalizumab Trial

50 patients enrolled; Dose escalation ongoing	Patients treated with full-dose PDR001 and increasing dosing of intratumoral ADU-S100 (50-400mcg)
Safety profile consistent with monotherapy study	No DLTs have been reported
Clinical responses observed in several tumor types	• Two patients had previously demonstrated responses to checkpoint inhibitor therapy alone • Reduced tumor volume in injected and non-injected lesions in some patients • Several patients remained on study >6 months

Aduro Biotech. (2018). *Aduro Biotech Presents Preliminary Results from Ongoing Phase 1 Trials of STING agonist ADU-S100 (MIW815) in Patients with Advanced Solid Tumors or Lymphomas* [Press release]. Retrieved from http://investors.aduro.com/phoenix.zhtml?c=242043&p=irol-newsArticle&ID=2376492

ADURO BIOTECH

Clinical Observations to-date Support MOA of ADU-S100 (MIW815)

Dose expansions and further exploration in homogenous populations – important next steps to assess ADU-S100 (MIW815) potential



BION-1301
APRIL Antibody



Multiple Myeloma Cell Survival and Proliferation Enhanced by APRIL Produced in Bone Marrow Niche



- **APRIL: A Proliferation Inducing Ligand**
  - Soluble factor that binds to BCMA and TACI receptors and induces signaling
  - Implicated in Multiple Myeloma (MM), CLL, CRC, and IgA Nephropathy
- Blocking APRIL is **a distinct approach to inhibit both BCMA and TACI** that appears to have immunomodulatory properties

ADURO BIOTECH

Key Attributes of BION-1301 First-in-Class APRIL Antibody

- BION-1301 **fully blocking** antibody, blocks APRIL binding to **both receptors BCMA and TACI**
- Preclinical data support **biological and scientific rationale in MM** and expansion into combinations and adjacent cancer indications
  - Blocking APRIL inhibits MM tumor growth, drug resistance and immune suppression
  - Demonstrated single agent activity inhibiting myeloma cells and regulatory T cells
- **Well-tolerated** in preclinical and early clinical study
- **Wholly-owned asset with opportunity in IgA Nephropathy** and other diseases



Guadagnoli M et al., Blood (2011)

Phase 1/2 BION-1301 Multiple Myeloma Trial Ongoing



ADURO BIOTECH

BION-1301 Mechanism of Action has Potential to Affect Multiple Steps of IgA Nephropathy Pathogenesis

High unmet medical need and no approved drugs for IgA Nephropathy



Pietro A. Canetta et al. CJASN 2014

ADURO BIOTECH

Preclinical Data Provides Compelling Rationale for BION-1301 in IgA Nephropathy

Mice





Non Human Primates



ADURO BIOTECH

Phase 1 BION-1301 Trial in Healthy Volunteers and IgAN Patients

First-in-Human study designed to enable dose selection and generate proof of mechanism data



ADURO BIOTECH

Business Overview



Aduro Strategic Collaborations and Partnerships

	Program	Collaboration	Indication	Terms	Commercial
STING	**ADU-S100 and other agonists**	NOVARTIS	Oncology	• $700M upfront & potential milestones • $50M equity • Co-development & co-commercialization	• Aduro leads US sales • Profit/expense share U.S., major EU and Japan • Royalties ROW
	cGAS-STING pathway inhibitor program	Lilly	Autoimmune	• $12M upfront • $620M potential development and commercial milestones per product • Research funding	• Lilly responsible for global commercialization • Single to low-double digit royalties • Option to co-fund clinical development in exchange for increased royalties
B-select	**Anti-CD27 agonist**	MERCK	Oncology	• $447M potential milestones • Global license	• Mid single-digit to low teens royalties

Strong Financial Position and Broad Intellectual Property Portfolio

3Q 2018 Financials

Cash & cash equivalents as of September 30, 2018	$278.6M
Operating expenses for 3Q 2018	$28M
Shares outstanding as of September 30, 2018	79.1M

Extensive Patent Portfolio

Global Rights (includes in-licensed patents)

- >150 issued composition and methods patents
- >300 pending applications

Nominal Expiration

- STING: 2025-39
- BION-1301: 2030-38

Upcoming Anticipated Milestones

		H1 2019	H2 2019
STING	**ADU-S100 + ipilimumab** Initiate Phase 1 dose escalation in PD-1 R/R melanoma	●	
	ADU-S100 + spartalizumab Initiate Phase 1 dose expansion		●
	ADU-S100 + spartalizumab Report Phase 1 dose escalation results		●
	ADU-S100 + anti-PD-1 Initiate Phase 1b/2 dose escalation in earlier line head and neck cancer		●
APRIL	**BION-1301** Initiate Phase 1 IgAN study in healthy volunteers	●	
	BION-1301 Report Phase 1 MM dose escalation results		●
	BION-1301 Initiate Phase 2 MM dose expansion study		●


ADURO
BIOTECH™